Precigen, Inc. (NASDAQ:PGEN) Receives $7.00 Consensus PT from Analysts

Precigen, Inc. (NASDAQ:PGEN) has been assigned a consensus rating of “Moderate Buy” from the five ratings firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $7.00.

Several research analysts recently weighed in on PGEN shares. JMP Securities reaffirmed a “market outperform” rating and issued a $5.00 target price on shares of Precigen in a report on Tuesday, January 14th. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price objective (up previously from $4.00) on shares of Precigen in a research note on Thursday, January 23rd.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. ProShare Advisors LLC lifted its position in shares of Precigen by 26.6% in the fourth quarter. ProShare Advisors LLC now owns 51,822 shares of the biotechnology company’s stock worth $58,000 after buying an additional 10,900 shares in the last quarter. Cetera Investment Advisers raised its holdings in shares of Precigen by 8.9% during the 4th quarter. Cetera Investment Advisers now owns 283,562 shares of the biotechnology company’s stock worth $318,000 after acquiring an additional 23,250 shares in the last quarter. Cary Street Partners Financial LLC purchased a new stake in shares of Precigen during the 4th quarter worth approximately $98,000. Bank of America Corp DE boosted its position in shares of Precigen by 11.6% during the 4th quarter. Bank of America Corp DE now owns 207,300 shares of the biotechnology company’s stock valued at $232,000 after acquiring an additional 21,626 shares during the last quarter. Finally, BNP Paribas Financial Markets purchased a new position in shares of Precigen in the fourth quarter valued at $27,000. Hedge funds and other institutional investors own 33.51% of the company’s stock.

Precigen Price Performance

PGEN opened at $1.97 on Friday. The company has a 50 day simple moving average of $1.25 and a two-hundred day simple moving average of $1.06. The firm has a market cap of $576.95 million, a P/E ratio of -3.58 and a beta of 1.66. Precigen has a 1-year low of $0.65 and a 1-year high of $2.17.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.